{"title":"Essure®之路已走到尽头。","authors":"David H Horwell","doi":"10.1136/jfprhc-2017-101850","DOIUrl":null,"url":null,"abstract":"I am writing to draw readers’ attention to a letter dated 31 May 2017 addressed to UK healthcare professionals from Bayer plc, in which that company announced that it had decided to discontinue sales of Essure®, their hysteroscopic female sterilisation device, from 1 September 2017.\n\nEssure uses metal and polyester fibre ‘microinserts’ that are passed into the proximal parts of the fallopian tubes to occlude them by fibrosis. It was approved for use in the USA in 2002 and in the UK by NICE, the National Institute for Health and Clinical Excellence, in 2009.1 The device was reviewed in this journal in …","PeriodicalId":15734,"journal":{"name":"Journal of Family Planning and Reproductive Health Care","volume":"43 3","pages":"240-241"},"PeriodicalIF":0.0000,"publicationDate":"2017-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1136/jfprhc-2017-101850","citationCount":"4","resultStr":"{\"title\":\"End of the road for Essure?<b>®</b>.\",\"authors\":\"David H Horwell\",\"doi\":\"10.1136/jfprhc-2017-101850\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"I am writing to draw readers’ attention to a letter dated 31 May 2017 addressed to UK healthcare professionals from Bayer plc, in which that company announced that it had decided to discontinue sales of Essure®, their hysteroscopic female sterilisation device, from 1 September 2017.\\n\\nEssure uses metal and polyester fibre ‘microinserts’ that are passed into the proximal parts of the fallopian tubes to occlude them by fibrosis. It was approved for use in the USA in 2002 and in the UK by NICE, the National Institute for Health and Clinical Excellence, in 2009.1 The device was reviewed in this journal in …\",\"PeriodicalId\":15734,\"journal\":{\"name\":\"Journal of Family Planning and Reproductive Health Care\",\"volume\":\"43 3\",\"pages\":\"240-241\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1136/jfprhc-2017-101850\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Family Planning and Reproductive Health Care\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/jfprhc-2017-101850\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Family Planning and Reproductive Health Care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/jfprhc-2017-101850","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q","JCRName":"Medicine","Score":null,"Total":0}
I am writing to draw readers’ attention to a letter dated 31 May 2017 addressed to UK healthcare professionals from Bayer plc, in which that company announced that it had decided to discontinue sales of Essure®, their hysteroscopic female sterilisation device, from 1 September 2017.
Essure uses metal and polyester fibre ‘microinserts’ that are passed into the proximal parts of the fallopian tubes to occlude them by fibrosis. It was approved for use in the USA in 2002 and in the UK by NICE, the National Institute for Health and Clinical Excellence, in 2009.1 The device was reviewed in this journal in …
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
